Core Viewpoint - The company, Wantai Biological Pharmacy Enterprise Co., Ltd., has successfully bid for the national immunization program's procurement project for the bivalent human papillomavirus (HPV) vaccine, which is expected to enhance its market presence and contribute to cervical cancer elimination efforts in China [1][2]. Group 1: Vaccine Procurement and Market Impact - The company's bivalent HPV vaccine (E. coli) has been included in the national procurement project with a unit price of 27.5 yuan [1]. - The inclusion of the vaccine is anticipated to increase the vaccination rate in China and support the country's goal of eliminating cervical cancer [1]. - The company acknowledges that the domestic market for bivalent HPV vaccines is under pressure due to the availability of imported nine-valent HPV vaccines and changing consumer preferences [2]. Group 2: Recent Developments and Financial Performance - The company has received acceptance for its clinical trial application for a recombinant respiratory syncytial virus vaccine, marking a significant step in its vaccine development strategy [2]. - For the first three quarters of the year, the company reported revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net loss of 173 million yuan [3]. - In the third quarter, the company achieved revenue of 655 million yuan, reflecting a year-on-year growth of 12.5%, but still reported a net loss of approximately 29.38 million yuan [3].

Core Viewpoint - Company WanTai BioPharma (603392.SH) has successfully entered the bidding for the 2025 National Immunization Program vaccine procurement project for the bivalent human papillomavirus (HPV) vaccine, with a unit price of RMB 27.5 [1][2] Group 1 - The bivalent HPV vaccine (E. coli) is designed to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer and various grades of cervical intraepithelial neoplasia (CIN) [1] - The company has responded to the World Health Organization's initiative to eliminate cervical cancer globally, with approximately 80 million doses of the product sold worldwide as of the announcement date [1] - The inclusion of the product in the procurement project is expected to enhance HPV vaccination rates in China, contributing to the country's goal of eliminating cervical cancer [1] Group 2 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, and if the company signs procurement contracts and organizes production and supply, it will help expand the sales scale of the included product [2] - This development is anticipated to increase the market share of the company's included products and enhance its brand influence in the domestic market [2]

Core Viewpoint - Company’s subsidiary has successfully participated in a national vaccine procurement project, which could enhance its market presence and brand influence [1] Group 1: Company Developments - WanTai Biological's subsidiary, Xiamen WanTai Canghai Biotechnology Co., Ltd., has entered the bidding for the national immunization program's dual-valent human papillomavirus vaccine procurement project [1] - The dual-valent human papillomavirus vaccine (E. coli) has been shortlisted for the procurement [1] Group 2: Market Implications - If the company signs a procurement contract and organizes production and supply, it will help expand the sales scale of the shortlisted products [1] - This development is expected to improve the company's market share and facilitate the domestic market expansion of its shortlisted products [1] - The initiative will also enhance the company's brand influence in the market [1]

本次集中采购是中国疾病预防控制中心组织的国家免疫规划疫苗集中采购项目，若公司后续签订采购合 同并组织生产与供应，将有利于扩大入围产品的销售规模，提高市场占有率，促进公司入围产品国内市 场的开拓，提升公司的品牌影响力。 智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限 公司参加了2025年国家免疫规划疫苗集中采购项目—双价人乳头瘤病毒疫苗采购项目的投标工作，公司 双价人乳头瘤病毒疫苗(大肠埃希菌)入围。 ...